标题：匹多莫德辅助治疗细菌感染性肺炎的疗效及其对患儿血清炎性因子和Th1/Th2细胞因子的影响

      作者：陈萍 1，夏训和 2    上海市金山区亭林医院儿科 1、检验科 2，上海 201505

      卷次： 2019年30卷5期

      【摘要】 目的 观察匹多莫德辅助治疗细菌感染性肺炎的临床疗效，并探讨其对患儿血清炎性因子和Th1/Th2细胞因子影响。方法 随机选择2016年3月至2018年5月上海市金山区亭林医院儿科收治的91例细菌感染性肺炎患儿，并按照入院先后顺序分为两组，2017年4月以前入院患儿纳入对照组(n=45)，采用常规治疗，2017年4月以后入院患儿纳入观察组(n=46)，在对照组基础上加匹多莫德辅助治疗，治疗2个月后，比较两组患儿的临床疗效、症状改善时间、炎性因子和Th1/Th2细胞因子含量的差异。结果 观察组患儿的临床治疗总有效率为95.65%，明显高于对照组的77.78%，差异有统计学意义(P<0.05)；观察组患儿的发热消退时间、咳嗽消失时间、肺部啰音消失时间分别为(2.52±1.13) d、(4.82±2.64) d、(6.13±2.71) d，均明显短于对照组的(3.21±1.32) d、(6.64±2.91) d、(7.93±3.06) d，差异均有统计学意义(P<0.05)；治疗前两组患儿的Th1细胞因子干扰素γ (INF-γ)、Th2细胞因子白介素-4 (IL-4)、INF-γ/IL-4水平比较差异均无统计学意义(P>0.05)；治疗后两组患儿 INF-γ、IL-4、INF-γ/IL-4均明显改善，但观察组改善程度更明显，差异均有统计学意义(P<0.05)；两组患儿治疗前的降钙素原(PCT)、CRP及白细胞(WBC)比较差异均无统计学意义(P>0.05)；治疗后两组患儿的上述指标均有所好转，其中观察组明显优于同期对照组，差异均有统计学意义(P<0.05)。结论 匹多莫德辅助治疗能够提升细菌感染性肺炎患儿临床疗效，改善机体炎症反应及扭转Th1/Th2系统失衡状态，具有临床推广应用价值。
      【关键词】 匹多莫德；细菌；肺炎；炎性因子；症状；免疫功能
      【中图分类号】 R725.6 【文献标识码】 A 【文章编号】 1003—6350（2019）05—566—03T

herapeutic effect of Pidotimod in adjunctive therapy for bacterial infectious pneumonia and its effect on seruminflammatory factors and Th1/Th2 cytokines in children.
CHEN Ping 1, XIA Xun-he 2. Department of Paediatrics 1,Department of Laboratory 2, Shanghai Jinshan Tinglin Hospital, Shanghai 201505, CHINA
【Abstract】 Objective To observe the clinical efficacy of Pidotimod in adjunctive therapy for bacterial infec-tious pneumonia, and to explore its effect on serum inflammatory factors and Th1/Th2 cytokines in children.Methods A total of 91 children with bacterial infection pneumonia admitted to the Department of Pediatrics at Shang-hai Jinshan Tinglin Hospital from March 2016 to May 2018 were randomly selected and divided into two groups accord-ing to the order of admission. Children admitted to the hospital before April 2017 were included in the control group (n=45) with routine treatment. Children admitted to the hospital after April 2017 were included in the observation group (n=46) and given adjunctive therapy with pidotimod based on the treatment of the control group. After 2 months of treat-ment, the clinical efficacy, symptom improvement time, inflammatory factors and Th1/Th2 cytokine levels were com-pared between the two groups. Results The total effective rate in the observation group was 95.65%, which was signifi-cantly higher than 77.78% in the control group (P<0.05). The time of fever regression, the time of cough disappearance,and the disappearance time of lung rales in the observation group were respectively (2.52±1.13) d, (4.82±2.64) d, and(6.13±2.71) d, which were significantly shorter than corresponding (3.21±1.32) d, (6.64±2.91) d, (7.93±3.06) d in thecontrol group (P<0.05). There were no significant differences in the levels of Th1 cytokine interferon gamma (INF-γ),Th2 cytokine interleukin-4 (IL-4), and INF-γ/IL-4 ratio between the two groups before treatment; while INF-γ, IL-4,and INF-γ/IL-4 ratio were significantly improved in the two groups, and the improvements in the observation groupwere more significant (P<0.05). There were no significant differences in procalcitonin (PCT), C-reactive protein (CRP),and white blood cells (WBC) between the two groups (P>0.05); while after treatment, the above indicators were im-proved in both groups, and the observation group was significantly better than the control group. Conclusion Adju-vant therapy with Pidotimod can improve the clinical efficacy of children with bacterial infectious pneumonia, improvethe body's inflammatory response and reverse the imbalance of Th1/Th2 system, and have clinical application value.
      【Key words】 Pidotimod; Bacteria; Pneumonia; Inflammatory factors; Symptoms; Immune function